Which CYP2B6 Variants Have Functional Consequences for Cyclophosphamide Bioactivation?

被引：9
|
作者：
Helsby, Nuala A. [1 ]
Tingle, Malcolm D. [1 ]
机构：
[1] Univ Auckland, Fac Med & Hlth Sci, Auckland 1, New Zealand
来源：
DRUG METABOLISM AND DISPOSITION | 2012年 / 40卷 / 03期
关键词：
BREAST-CANCER PATIENTS; PULSE CYCLOPHOSPHAMIDE; CYTOCHROME P4502C19; LUPUS NEPHRITIS; POLYMORPHISMS; PHARMACOGENETICS; TOXICITY; CYP2C19; METABOLISM; GENOTYPE;
D O I：
10.1124/dmd.111.043646
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
引用
收藏
页码：635 / 637
页数：3
相关论文
共 50 条
  • [21] Functional characterization of 40 CYP2B6 allelic variants by assessing efavirenz 8-hydroxylation
    Watanabe, Takashi
    Saito, Takahiro
    Rico, Evelyn Marie Gutierrez
    Hishinuma, Eiji
    Kumondai, Masaki
    Maekawa, Masamitsu
    Oda, Akifumi
    Saigusa, Daisuke
    Saito, Sakae
    Yasuda, Jun
    Nagasaki, Masao
    Minegishi, Naoko
    Yamamoto, Masayuki
    Yamaguchi, Hiroaki
    Mano, Nariyasu
    Hirasawa, Noriyasu
    Hiratsuka, Masahiro
    [J]. BIOCHEMICAL PHARMACOLOGY, 2018, 156 : 420 - 430
  • [22] THE EXTENT OF INHIBITION AND INDUCTION OF CYP2B6 BY EFAVRIENZ IS CYP2B6 GENOTYPE-DEPENDENT
    Duong, A.
    Gufford, B.
    Masters, A.
    Burgess, K.
    Lu, J.
    Metzger, I.
    Desta, Z.
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2019, 105 : S36 - S36
  • [23] Identification and functional significance of polymorphisms in the human CYP2B6 gene
    Lang, T
    Klein, K
    Fischer, J
    Eichelbaum, M
    Schwab, M
    Zanger, UM
    [J]. NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 2001, 363 (04) : R126 - R126
  • [24] Inhibitory Effects Of Three Antineoplastic Drugs On CYP2B6 Allelic Variants
    Gao, Yiwen
    Men, Xin
    Guo, Jing
    Zhu, Juan-Li
    Chen, Chao
    [J]. DRUG METABOLISM REVIEWS, 2009, 41 : 38 - 38
  • [25] PharmVar GeneFocus: CYP2B6
    Desta, Zeruesenay
    El-Boraie, Ahmed
    Gong, Li
    Somogyi, Andrew A.
    Lauschke, Volker M.
    Dandara, Collet
    Klein, Kathrin
    Miller, Neil A.
    Klein, Teri E.
    Tyndale, Rachel F.
    Whirl-Carrillo, Michelle
    Gaedigk, Andrea
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2021, 110 (01) : 82 - 97
  • [26] Nicotine oxidation by genetic variants of CYP2B6 and in human brain microsomes
    Bloom, Adam Joseph
    Wang, Pan-Fen
    Kharasch, Evan D.
    [J]. PHARMACOLOGY RESEARCH & PERSPECTIVES, 2019, 7 (02):
  • [27] Novel CYP2B6 Enzyme Variants in a Rwandese Population: Functional Characterization and Assessment of In Silico Prediction Tools
    Radloff, Robert
    Gras, Alain
    Zanger, Ulrich M.
    Masquelier, Cecile
    Arumugam, Karthik
    Karasi, Jean-Claude
    Arendt, Vic
    Seguin-Devaux, Carole
    Klein, Kathrin
    [J]. HUMAN MUTATION, 2013, 34 (05) : 725 - 734
  • [28] Improvement of cyclophosphamide activation by CYP2B6 mutants:: From in silico to ex vivo
    Nguyen, Thien-An
    Tychopoulos, Marina
    Bichat, Florence
    Zimmermann, Clothilde
    Flinois, Jean-Pierre
    Diry, Monique
    Ahlberg, Emelie
    Delaforge, Marcel
    Corcos, Laurent
    Beaune, Philippe
    Dansette, Patrick
    Andre, Francois
    de Waziers, Isabelle
    [J]. MOLECULAR PHARMACOLOGY, 2008, 73 (04) : 1122 - 1133
  • [29] Plausible drug interaction between cyclophosphamide and voriconazole via inhibition of CYP2B6
    Shibata, Yukihiro
    Tamemoto, Yuta
    Singh, Sheelendra Pratap
    Yoshitomo, Aoi
    Hozuki, Shizuka
    Sato, Hiromi
    Hisaka, Akihiro
    [J]. DRUG METABOLISM AND PHARMACOKINETICS, 2021, 39
  • [30] Role of CYP2B6 and ALDH1A1 in medulloblastoma resistance to cyclophosphamide
    Ulises Tamayo-Chuc, Darwin
    Gilberto Garza-Gonzalez, Alan
    [J]. GACETA MEXICANA DE ONCOLOGIA, 2015, 14 (01): : 46 - 52
12345